Hepatitis C and autoimmunity: a therapeutic challenge.

Area of Science:

• Hepatology
• Immunology
• Dermatology

Background:

• Hepatitis C virus (HCV) infection is known to cause liver disease and various extrahepatic manifestations.
• The association between HCV and autoimmune conditions is increasingly recognized, though specific co-occurrences are rare.

Observation:

• This case report details a patient with chronic HCV infection who simultaneously developed subacute cutaneous lupus erythematosus (SCLE).
• The patient also presented with a small CD20+ B-cell clone, indicating a potential link between the viral infection and lymphoproliferative disorders.
• These conditions emerged despite standard therapy for HCV (pegylated interferon plus ribavirin), suggesting treatment resistance or complex immune dysregulation.

Findings:

• The simultaneous occurrence of SCLE and a CD20+ B-cell clone in the context of chronic HCV infection is unprecedented.
• Standard HCV treatment failed to resolve these extrahepatic manifestations, highlighting the need for alternative therapeutic strategies.
• Successful treatment of both SCLE and the B-cell clone was achieved using rituximab, a monoclonal antibody targeting CD20+ B-cells.

Implications:

• This case suggests a potential pathogenic link between HCV, SCLE, and CD20+ B-cell abnormalities.
• Rituximab may be an effective therapeutic option for patients with HCV-associated SCLE and B-cell clones.
• Further research is warranted to elucidate the mechanisms underlying these co-occurrences and the efficacy of targeted immunotherapies.